Ind-Swift Laboratories' Financial Performance Shows Significant Decline in Q2 FY25

Ind-Swift Laboratories, a microcap pharmaceutical company, recently declared its financial results for the quarter ending September 2024. According to the report, the company has seen a very negative performance in the quarter, with a score of -21 compared to -11 in the previous quarter.

The company’s profit after tax (PAT) for the half-yearly period has decreased by 97.24% year on year, and the net sales have also fallen by 95.87% year on year. The profit before tax less other income (PBT) has also seen a significant decline of 139.62% year on year. This trend is expected to continue in the near term.

The company’s operating profit (PBDIT) for the quarter has reached its lowest point in the last five quarters, and the operating profit margin has also decreased to -98.58%. This indicates a deterioration in the company’s efficiency.

Moreover, the company’s non-operating income is 2,243.10% of its profit before tax, which suggests that the company’s income from non-business activities is high and not sustainable in the long run.

The earnings per share (EPS) for the quarter has also decreased to its lowest point in the last five quarters, indicating a decline in profitability and lower earnings for shareholders.

Based on these financial results, MarketsMOJO has given a ‘Strong Sell’ call for Ind-Swift Laboratories’ stock. Investors should carefully consider these factors before making any investment decisions.